Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation.
- Author:
Si-Si CHEN
1
;
Qian SUN
2
;
Lan CAO
2
;
Wen-Zhong WU
1
;
Yue XIE
1
;
Chun QIAO
2
;
Jian-Yong LI
2
;
Si-Xuan QIAN
2
;
Ming HONG
2
Author Information
- Publication Type:Journal Article
- From: Chinese Medical Journal 2020;134(12):1477-1479
- CountryChina
- Language:English
